Establishment of a novel double‐monoclonal antibody sandwich enzyme‐linked immunosorbent assay (ELISA): tool for human B7‐H4 detection in autoimmune diseases
Author(s) -
Ding Sisi,
Zhou Hengxin,
Gu Yanzheng,
Shen Yu,
Zhang Li,
Zhao Huayang,
Wu Jian,
Zhang Xueguang,
Chang Xin,
Liu Cuiping
Publication year - 2021
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.13610
Subject(s) - monoclonal antibody , immunology , epitope , cytokine , flow cytometry , autoimmune disease , antibody , medicine , t cell , autoimmunity , biology , immune system
Summary B7‐H4, one of the immunoregulatory proteins, plays an inhibitory role by inhibiting T cell proliferation and cytokine production. Nevertheless, the significance of soluble B7‐H4 (sB7‐H4) in autoimmune diseases is unclear. In our study, we developed two novel mouse anti‐human B7‐H4 monoclonal antibodies (mAbs) (clones 8D4 and 7E1) with utilities for flow cytometry, immunoblotting and immunofluorescence. We characterized 7E1 as a functional antibody with antagonistic activity, which could promote T cell proliferation and regulate cytokine production. Furthermore, based on the different epitope specificities, we established a novel enzyme‐linked immunosorbent assay (ELISA) which could detect sB7‐H4 sensitively and specifically. Using this ELISA kit, sB7‐H4 was observed in a high proportion of autoimmune diseases patients. We found that the levels of sB7‐H4 were significantly higher in patients with systemic lupus erythematosus (SLE), type I diabetes (T1D) and Graves’ disease (GD). Together, sB7‐H4 in human serum is regarded not only as a regulator of T cell activation but may also be a diagnostic marker of autoimmune diseases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom